Ursodeoxycholic acid (UDCA), also known as ursodiol, is a secondary bile acid, produced in humans and most other species from metabolism by intestinal bacteria. It is synthesized in the liver in some species, and was first identified in bile of bears of genus Ursus, from which its name derived. [8]. How does URSOFALK work in the body? URSOFALK works by reducing bile acid production and promoting the flow of bile in the liver, helping to dissolve cholesterol gallstones and improving liver function. Ursofalk (ursodeoxycholic acid, UDCA) is used for the treatment of Primary Biliary Cholangitis (PBC), for the dissolution of radiolucent gallstones and for hepatobiliary disorders associated with Cystic Fibrosis. Ursodeoxycholic acid, the active ingredient in Ursofalk capsules, is a natural bile acid that is found in small amounts in the bile of humans. To dissolve small gallstones. For a liver disease (primary biliary cirrhosis) among other things to stimulate bile flow. Ursofalk is a naturally occurring bile acid used to treat different hepatobilliary disorders. The activity of Ursofalk is achieved through a decrease in secretion of cholesterol in bile. During the first 3 months of treatment, you should take Ursofalk Capsules in the morning, at midday and in the evening. As liver function values improve, the total daily dose may be taken once a day in the evening. Ursofalk 250mg Capsule is used to treat cholesterol gallstones, primary biliary cirrhosis, primary sclerosing cholangitis, and liver disease associated with cystic fibrosis. Patient information for URSOFALK 250MG CAPSULES Including dosage instructions and possible side effects. URSOFALK - Cápsulas Sustancia (s): Ácido Ursodeoxicólico Presentaciones: 1 Caja, 50 Cápsulas, 250 mg 1 Caja, 60 Cápsulas, 250 mg URSOFALK is a bile acid, which may have a protective effect on the liver by reducing the absorption of other potentially toxic bile salts. URSOFALK is used to treat liver diseases such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and cystic fibrosis (CF)-related cholestasis.